MLYS Earnings Mineralys Therapeutics, Inc.
Reported diluted EPS by fiscal period (SEC EDGAR). Chart & overview →
1–17 of 17
| Q1 2026 | 2026-03-31 | -0.47 | 2026-05-06 | 10-Q |
| FY 2025 | 2025-12-31 | -2.29 | 2026-03-12 | 10-K |
| Q3 2025 | 2025-09-30 | -1.94 | 2025-11-10 | 10-Q |
| Q2 2025 | 2025-06-30 | -1.44 | 2025-08-12 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.79 | 2026-05-06 | 10-Q |
| FY 2025 | 2024-12-31 | -3.66 | 2026-03-12 | 10-K |
| Q3 2025 | 2024-09-30 | -2.68 | 2025-11-10 | 10-Q |
| Q2 2025 | 2024-06-30 | -1.54 | 2025-08-12 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.70 | 2025-05-12 | 10-Q |
| FY 2024 | 2023-12-31 | -1.99 | 2025-02-12 | 10-K |
| Q3 2024 | 2023-09-30 | -1.36 | 2024-11-12 | 10-Q |
| Q2 2024 | 2023-06-30 | -0.77 | 2024-08-13 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.51 | 2024-05-09 | 10-Q |
| FY 2023 | 2022-12-31 | -5.77 | 2024-03-21 | 10-K |
| Q3 2023 | 2022-09-30 | -4.02 | 2023-11-07 | 10-Q |
| Q2 2023 | 2022-06-30 | -2.73 | 2023-08-07 | 10-Q |
| Q1 2023 | 2022-03-31 | -1.48 | 2023-05-15 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Informational only — not financial advice.